胰岛素信号传导：帕金森病治疗的新靶点？ - Suppr

Suppr

超能文献

Insulin signalling: new target for Parkinson's treatments?

作者信息

Poewe Werner, Seppi Klaus

机构信息

Department of Neurology, Medical University Innsbruck, Anichstrasse 35, AT-6020 Innsbruck, Austria.

出版信息

Lancet. 2017 Oct 7;390(10103):1628-1630. doi: 10.1016/S0140-6736(17)32101-3. Epub 2017 Aug 3.

DOI:10.1016/S0140-6736(17)32101-3

PMID:28781109

Abstract

摘要

相似文献

Insulin signalling: new target for Parkinson's treatments?

Lancet. 2017 Oct 7;390(10103):1628-1630. doi: 10.1016/S0140-6736(17)32101-3. Epub 2017 Aug 3.

Insulin resistance and Parkinson's disease: A new target for disease modification?

Prog Neurobiol. 2016 Oct-Nov;145-146:98-120. doi: 10.1016/j.pneurobio.2016.10.001. Epub 2016 Oct 3.

Parkinson's disease, insulin resistance and novel agents of neuroprotection.

Brain. 2013 Feb;136(Pt 2):374-84. doi: 10.1093/brain/aws009. Epub 2012 Feb 17.

Treatment of Parkinson's disease : what's on the horizon?

CNS Drugs. 2005;19(9):723-43. doi: 10.2165/00023210-200519090-00001.

Dementia is associated with insulin resistance in patients with Parkinson's disease.

J Neurol Sci. 2012 Apr 15;315(1-2):39-43. doi: 10.1016/j.jns.2011.12.008. Epub 2012 Jan 21.

Toward neuroprotective treatments of Parkinson's disease.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3795-3797. doi: 10.1073/pnas.1703362114. Epub 2017 Mar 30.

Preclinical development of gene therapy for Parkinson's disease.

Exp Neurol. 2008 Jan;209(1):72-81. doi: 10.1016/j.expneurol.2007.08.003. Epub 2007 Aug 22.

After the diagnosis: living with Parkinson's. There's no cure for Parkinson's disease, but new treatments can ease the symptoms and prolong independence.

Harv Womens Health Watch. 2006 Jun;13(10):2-4.

Trial designs used to study neuroprotective therapy in Parkinson's disease.

Mov Disord. 2013 Jan;28(1):86-95. doi: 10.1002/mds.24997. Epub 2012 Aug 23.

Designing neuroprotection trials in Parkinson's disease.

Ann Neurol. 2003;53 Suppl 3:S100-7; discussion S107-9. doi: 10.1002/ana.10484.

引用本文的文献

Potential molecular mechanism of exercise reversing insulin resistance and improving neurodegenerative diseases.

Front Physiol. 2024 May 16;15:1337442. doi: 10.3389/fphys.2024.1337442. eCollection 2024.

Myrcene Salvages Rotenone-Induced Loss of Dopaminergic Neurons by Inhibiting Oxidative Stress, Inflammation, Apoptosis, and Autophagy.

Molecules. 2023 Jan 10;28(2):685. doi: 10.3390/molecules28020685.

Striatal DAT availability does not change after supraphysiological glucose loading dose in humans.

Endocr Connect. 2021 Oct 7;10(10):1266-1272. doi: 10.1530/EC-21-0355.

Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse.

ACS Chem Neurosci. 2018 Apr 18;9(4):809-816. doi: 10.1021/acschemneuro.7b00434. Epub 2018 Jan 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Insulin signalling: new target for Parkinson's treatments?

Lancet. 2017 Oct 7;390(10103):1628-1630. doi: 10.1016/S0140-6736(17)32101-3. Epub 2017 Aug 3.

Insulin resistance and Parkinson's disease: A new target for disease modification?

Prog Neurobiol. 2016 Oct-Nov;145-146:98-120. doi: 10.1016/j.pneurobio.2016.10.001. Epub 2016 Oct 3.

Parkinson's disease, insulin resistance and novel agents of neuroprotection.

Brain. 2013 Feb;136(Pt 2):374-84. doi: 10.1093/brain/aws009. Epub 2012 Feb 17.

Treatment of Parkinson's disease : what's on the horizon?

CNS Drugs. 2005;19(9):723-43. doi: 10.2165/00023210-200519090-00001.

Dementia is associated with insulin resistance in patients with Parkinson's disease.

J Neurol Sci. 2012 Apr 15;315(1-2):39-43. doi: 10.1016/j.jns.2011.12.008. Epub 2012 Jan 21.

Toward neuroprotective treatments of Parkinson's disease.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3795-3797. doi: 10.1073/pnas.1703362114. Epub 2017 Mar 30.

Preclinical development of gene therapy for Parkinson's disease.

Exp Neurol. 2008 Jan;209(1):72-81. doi: 10.1016/j.expneurol.2007.08.003. Epub 2007 Aug 22.

After the diagnosis: living with Parkinson's. There's no cure for Parkinson's disease, but new treatments can ease the symptoms and prolong independence.

Harv Womens Health Watch. 2006 Jun;13(10):2-4.

Trial designs used to study neuroprotective therapy in Parkinson's disease.

Mov Disord. 2013 Jan;28(1):86-95. doi: 10.1002/mds.24997. Epub 2012 Aug 23.

Designing neuroprotection trials in Parkinson's disease.

Ann Neurol. 2003;53 Suppl 3:S100-7; discussion S107-9. doi: 10.1002/ana.10484.

引用本文的文献

Potential molecular mechanism of exercise reversing insulin resistance and improving neurodegenerative diseases.

Front Physiol. 2024 May 16;15:1337442. doi: 10.3389/fphys.2024.1337442. eCollection 2024.

Myrcene Salvages Rotenone-Induced Loss of Dopaminergic Neurons by Inhibiting Oxidative Stress, Inflammation, Apoptosis, and Autophagy.

Molecules. 2023 Jan 10;28(2):685. doi: 10.3390/molecules28020685.

Striatal DAT availability does not change after supraphysiological glucose loading dose in humans.

Endocr Connect. 2021 Oct 7;10(10):1266-1272. doi: 10.1530/EC-21-0355.

Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse.

ACS Chem Neurosci. 2018 Apr 18;9(4):809-816. doi: 10.1021/acschemneuro.7b00434. Epub 2018 Jan 4.